Showing results (561-570 of 1,837) with videos related to

Sort By:
Pageof 184
ESMO Open|June 11, 2025
Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancersK Iida, Y Matsui, Y Urabe, et al.
ESMO Open|June 13, 2025
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)V Gambardella, M K Accordino, P L Bedard, et al.
ESMO Open|June 10, 2025
Financial toxicity and socioeconomic impact of cancer in EuropeJ Vancoppenolle, N Franzen, L Azarang, et al.
ESMO Open|June 14, 2025
Phase I study of H3B-6545 in patients with estrogen receptor-positive breast cancerK Yonemori, T Shimoi, K Yamamoto, et al.
ESMO Open|July 16, 2025
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patientsE A Martino, G Caridà, D Lofaro, et al.
ESMO Open|June 3, 2025
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT studyL García-Estévez, A Bardia, H S Rugo, et al.
ESMO Open|June 4, 2025
Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclibC Corti, A R Martin, P T Kurnia, et al.
ESMO Open|June 3, 2025
Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship careC Dauccia, E Agostinetto, L Arecco, et al.
ESMO Open|May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LAD P Carbone, T-E Ciuleanu, M Cobo, et al.
ESMO Open|June 20, 2025
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trialR Fazio, G Randon, F Bergamo, et al.
Pageof 184